No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
165 |
4. Check minimum number of eventsNone |
165 |
5. Include endpointsNone |
165 |
6. Filter based on genotype QC (FinnGen only) |
165 |
Control definitions (FinnGen only)
- Control exclude
- E4_ENDOGLAND
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- E20-E35
- Name in latin
- Perturbationes adrenogenitales
Similar endpoints
↥List of similar endpoints to
Adrenogenital disorders
based on the number of shared cases.
Similar with more cases:
- Exclusions for E4_PCOS_BROAD
- Disorders of other endocrine glands
- Endocrine, nutritional and metabolic diseases
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1321 | 789 | 518 |
| Only index persons | 1074 | 671 | 403 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.01 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 53.68 | 48.68 | 61.35 |
| Only index persons | 49.85 | 44.47 | 58.80 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 165 | 101 | 64 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 50.92 | 45.35 | 59.71 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 148
- Matched controls
- 1479
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
E25.9
ICD-10 Finland
Adrenogenital disorder, unspecified
+∞
68.1
60
*
E25.00
ICD-10 Finland
Congenital salt-losing adrenal hyperplasia
+∞
42.8
39
*
E25.01
ICD-10 Finland
Congenital adrenal hyperplasia
+∞
41.6
38
*
105
Kela drug reimbursment
Adrenal cortical hypofunction
+∞
26.9
25
*
H02AB09
ATC
hydrocortisone; systemic
44.6
21.6
26
7
E25.8
ICD-10 Finland
Other adrenogenital disorders
+∞
19.2
18
*
123
Kela drug reimbursment
Chronic disorders of vitamin D metabolism
34.6
16.6
21
7
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
11.6
16.4
31
33
H02AA02
ATC
fludrocortisone; oral
36.0
15.2
19
6
A11CC03
ATC
alfacalcidol; systemic
24.2
15.2
21
10
E25.0
ICD-10 Finland
Congenital adrenogenital disorders associated with enzyme deficiency
+∞
13.8
13
*
E21.09
ICD-10 Finland
Other primary hyperparathyroidism
153.5
13.7
14
*
A12AA04
ATC
calcium carbonate; oral
44.4
13.4
16
*
E27.1
ICD-10 Finland
Primary adrenocortical insufficiency
+∞
11.6
11
*
25502
ICD-8 Finland
Diseases of adrenal glands, Virilismus adrenocorticalis
+∞
10.5
10
*
I25.9
ICD-10 Finland
Chronic ischaemic heart disease, unspecified
4.9
10.1
34
84
206
Kela drug reimbursment
Chronic coronary artery disease and dyslipidaemia associated with chronic coronary artery disease
3.7
9.0
43
147
E27.4
ICD-10 Finland
Other and unspecified adrenocortical insufficiency
+∞
8.4
8
*
2552A
ICD-9 Finland
Disorders of adrenal glands, Adrenogenital disorders[SYNDROMA ADRENOGENITALE CONGENITUM]
+∞
8.4
8
*
I25.1
ICD-10 Finland
Atherosclerotic heart disease
3.3
8.1
47
184
Z49.1
ICD-10 Finland
Extracorporeal dialysis
47.5
7.8
9
*
TK800
NOMESCO Finland
Hemodialysis
19.6
7.7
11
6
NK6QA
NOMESCO Finland
Measurement of bone density from tow or more locations with X-ray
6.1
7.6
20
37
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
2.9
7.5
53
238
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
16.8
7.3
11
7
321
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
7.3
7
*
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
3.2
7.3
43
170
V03AE01
ATC
polystyrene sulfonate; oral
31.7
7.2
9
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.6
7.0
33
110
A09
ICD-10 Finland
Other gastroenteritis and colitis of infectious and unspecified origin
3.2
7.0
39
148
N03AX16
ATC
pregabalin; oral
3.1
6.9
41
161
I15.1
ICD-10 Finland
Hypertension secondary to other renal disorders
17.7
6.8
10
6
I20.81
ICD-10 Finland
Other angina pectoris stenosed coronary artery
4.9
6.7
21
48
N18.8
ICD-10 Finland
Other chronic renal failure
10.8
6.7
12
12
E11.2
ICD-10 Finland
Type 2 diabetes mellitus, with renal complications
10.8
6.7
12
12
E11.7
ICD-10 Finland
Type 2 diabetes mellitus, with multiple complications
6.5
6.5
16
27
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
3.6
6.5
29
93
R53
ICD-10 Finland
Malaise and fatigue
2.8
6.4
45
198
127
Kela drug reimbursment
Transplant complication
28.0
6.3
8
*
L04AA06
ATC
mycophenolic acid; systemic
28.0
6.3
8
*
E21.3
ICD-10 Finland
Hyperparathyroidism, unspecified
+∞
6.3
6
*
196
Kela drug reimbursment
Paricalcitol and cinacalcet
+∞
6.3
6
*
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
21
0
+∞
22.40
8.3
0.0
68.8
—
nmol/l
—
21
0
37
89
5.07
15.07
6.8
3.7
162.0
76.3
ng/l
1.86
28
77
107
591
3.31
12.30
15.9
6.2
1.2
1.2
mmol/l
0.62
86
497
103
566
3.18
11.76
12.7
5.0
1.2
1.2
mmol/l
0.34
97
501
21
67
3.45
5.70
1.9
1.7
—
—
—
0
0
74
451
2.16
5.46
5.4
3.2
—
—
—
0
0
46
235
2.33
5.18
1.8
1.7
1056.2
1174.1
nmol/l
0.28
41
170
31
133
2.64
5.05
2.4
1.8
—
—
—
0
0
41
205
2.33
4.82
2.7
1.9
—
—
—
0
0
30
131
2.58
4.71
2.3
1.7
—
—
—
0
0
60
355
2.08
4.64
5.2
2.9
0.3
0.5
e6/l
0.71
48
255
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
10
22
4.77
4.36
2.7
2.5
0.3
0.4
u/ml
—
5
12
11
29
3.99
3.87
1.5
2.1
—
—
—
0
0
23
104
2.41
3.34
3.2
2.8
24.7
29.5
u/l
0.72
18
90
51
323
1.84
3.06
5.6
4.0
25.3
11.5
mg/mmol
0.87
38
207
94
721
1.71
2.84
7.7
4.2
7.2
6.5
mmol/l
1.54
89
663
10
32
3.26
2.69
1.2
1.5
—
—
—
0
0
67
476
1.69
2.65
2.6
2.0
90.9
94.7
pmol/l
0.30
38
239
31
176
1.94
2.57
2.0
2.0
29.6
29.6
s
0.01
31
170
5
7
7.32
2.56
4.4
6.0
—
—
—
0
0
36
224
1.78
2.24
6.2
3.2
36.8
107.1
ng/l
1.05
29
172
92
737
1.56
2.09
12.1
9.4
4.2
4.1
e9/l
0.05
79
645
84
660
1.56
2.07
7.0
5.7
9.8
10.2
umol/l
0.25
84
619
5
11
4.65
1.95
1.0
1.3
—
—
—
0
0
7
22
3.28
1.90
1.6
1.5
—
—
—
0
0
6
17
3.62
1.85
1.7
1.4
—
—
—
0
0
6
17
3.62
1.85
1.7
1.5
—
—
—
0
0
40
270
1.64
1.85
1.8
1.8
0.8
1.4
mg/l
0.89
32
209
7
23
3.13
1.82
1.4
1.5
—
—
—
0
0
11
47
2.44
1.82
6.5
3.0
—
—
—
0
0
6
19
3.24
1.67
1.0
1.1
—
—
—
0
0
31
207
1.61
1.49
4.5
2.7
0.9
0.9
e6/l
0.06
14
106
7
28
2.56
1.47
1.9
1.2
—
19.3
—
0
5
6
22
2.79
1.45
1.7
1.2
—
—
—
0
0
30
202
1.59
1.40
4.6
3.0
5.1
3.4
e6/l
0.28
13
103
14
75
1.95
1.39
2.1
1.2
—
—
—
0
0
21
130
1.71
1.34
5.5
3.4
—
—
—
0
0
0
40
0.00
1.34
0.0
1.4
—
—
—
0
0
106
923
1.42
1.31
5.4
3.9
15.3
11.7
mm/h
1.41
101
825
57
446
1.42
1.31
6.5
3.4
2.3
2.4
mmol/l
0.67
52
386
5
18
2.83
1.29
1.2
1.4
—
—
—
0
0
15
91
1.71
1.04
2.2
1.6
—
—
—
0
0
15
91
1.71
1.04
8.9
4.0
5.1
5.1
kpa
0.12
15
82
5
22
2.31
1.04
1.8
1.2
—
—
—
0
0
48
379
1.38
1.02
3.8
2.2
56.0
56.0
u/l
0.00
43
350
6
30
2.04
0.88
2.0
1.3
—
—
—
0
0
6
31
1.97
0.85
2.2
1.6
—
—
—
0
0
12
73
1.69
0.84
1.0
1.0
—
—
—
0
0
6
33
1.85
0.80
2.2
1.6
—
—
—
0
0
0
25
0.00
0.79
0.0
1.1
—
—
—
0
0
27
203
1.39
0.77
1.4
1.3
31.9
38.7
iu/ml
—
6
59
125
1163
1.31
0.74
23.0
13.0
76.3
82.6
ml/min/173m2
1.47
108
934
15
101
1.53
0.73
12.1
5.1
1.1
1.3
mmol/l
0.50
15
96
11
168
0.63
0.72
1.6
2.3
—
—
—
0
0
25
191
1.36
0.66
1.2
1.3
1.3
10.9
u/ml
—
9
71
72
635
1.24
0.65
6.3
5.2
0.0
0.0
estimate
0.00
21
120
105
970
1.23
0.58
5.0
3.9
14.9
14.8
pmol/l
0.28
100
857
6
37
1.64
0.56
3.0
2.0
—
—
—
0
0
12
82
1.50
0.56
1.9
2.4
76.3
65.1
ml/min/173m2
—
7
31
13
180
0.70
0.55
1.7
2.4
—
—
—
0
0
41
347
1.24
0.53
3.9
4.3
0.0
0.0
estimate
0.00
20
114
52
452
1.22
0.52
6.8
3.9
37.3
48.6
ng/l
0.42
41
309
70
635
1.18
0.44
4.5
3.9
0.0
0.0
estimate
0.00
22
120
5
31
1.63
0.43
1.4
1.3
—
—
—
0
0
8
56
1.45
0.43
3.0
2.4
—
—
—
0
0
11
79
1.42
0.42
1.3
1.9
—
—
—
0
0
0
15
0.00
0.41
0.0
1.1
—
2.9
—
0
8
0
16
0.00
0.41
0.0
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.3
—
7.3
—
0
9
0
17
0.00
0.41
0.0
2.0
—
—
—
0
0
0
17
0.00
0.41
0.0
2.0
—
—
—
0
0
0
17
0.00
0.41
0.0
2.0
—
—
—
0
0
13
98
1.35
0.39
1.3
2.1
—
—
—
0
0
5
36
1.40
0.38
1.6
1.3
—
—
—
0
0
89
830
1.16
0.38
3.6
2.9
45.5
43.5
u/l
0.15
82
774
70
642
1.16
0.37
4.5
4.0
0.0
0.0
estimate
0.00
22
113
91
853
1.15
0.35
3.5
3.3
—
—
—
0
0
7
52
1.36
0.31
3.4
2.1
—
—
—
0
0
35
311
1.16
0.28
1.5
1.2
1.4
1.1
u/ml
—
8
77
31
275
1.16
0.25
1.7
1.6
—
—
—
0
0
12
147
0.80
0.24
13.3
7.4
—
—
—
0
0
5
37
1.36
0.24
3.0
2.6
26.2
24.1
mmol/l
—
5
30
5
38
1.33
0.23
1.6
1.2
—
—
—
0
0
124
1203
1.12
0.22
5.1
4.2
4.4
4.6
mmol/l
1.67
118
1106
8
103
0.77
0.22
1.6
1.6
—
—
—
0
0
0
11
0.00
0.21
0.0
1.3
—
10.1
—
0
11
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
1.7
—
6.9
—
0
5
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
2.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
1.2
—
0
5
0
13
0.00
0.21
0.0
1.7
—
13.6
—
0
13
0
14
0.00
0.20
0.0
1.4
—
203.9
—
0
14
6
50
1.21
0.20
1.0
1.6
—
—
—
0
0
130
1269
1.12
0.19
27.0
13.9
24.5
24.0
mg/l
0.06
111
1008
118
1148
1.10
0.17
26.7
14.2
39.7
39.8
%
0.07
85
850
126
1232
1.10
0.15
5.7
4.7
2.6
2.7
mmol/l
1.16
120
1118
52
492
1.08
0.15
4.9
4.0
—
—
—
0
0
122
1198
1.07
0.11
5.1
4.2
1.4
1.5
mmol/l
0.44
115
1090
5
44
1.14
0.10
1.0
1.2
—
—
—
0
0
5
45
1.11
0.10
1.0
1.2
—
—
—
0
0
5
47
1.07
0.09
1.4
1.1
—
—
—
0
0
5
47
1.07
0.09
3.6
1.5
2.5
3.0
mg/l
—
5
30
31
293
1.07
0.08
3.3
2.1
—
—
—
0
0
59
575
1.04
0.05
5.7
3.8
—
—
—
0
0
24
228
1.06
0.05
3.1
4.5
27.0
21.3
%
0.68
12
118
31
299
1.05
0.04
3.6
4.9
1.8
2.4
ug/l
0.60
26
259
21
200
1.06
0.04
1.8
1.4
—
—
—
0
0
116
1150
1.03
0.03
4.7
3.8
1.4
1.2
mmol/l
2.25
110
1046
119
1186
1.01
0.00
6.5
4.4
6.0
5.8
mmol/l
0.56
114
1068
15
152
0.99
0.00
5.9
4.5
35.9
31.2
%
1.18
15
92
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
100.4
—
0
9
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
7
70
1.00
0.00
1.0
1.3
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
9
0.00
0.00
0.0
2.4
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
3.0
—
—
—
0
0
0
7
0.00
0.00
0.0
2.9
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint E4_ADRENOGEN and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADRENOGEN | 2.292 [1.79, 2.93] | < 0.001 |
| Birth year | 0.995 [0.99, 1.0] | 0.259 |
During the follow-up period (1.1.1998 — 31.12.2019), 185 out of 572 females with E4_ADRENOGEN died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| E4_ADRENOGEN | 2.783 [1.92, 4.04] | < 0.001 |
| Birth year | 0.984 [0.97, 0.99] | < 0.001 |
During the follow-up period (1.1.1998 — 31.12.2019), 182 out of 401 males with E4_ADRENOGEN died.
Mortality risk
Mortality risk for people of age
years, who have E4_ADRENOGEN.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.204% | 0.453% |
| 5 | 1.287% | 2.978% |
| 10 | 3.461% | 7.181% |
| 15 | 6.431% | 13.75% |
| 20 | 11.168% | 22.495% |
Relationships between endpoints
↥Index endpoint: E4_ADRENOGEN – Adrenogenital disorders
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data